MEI Pharma Reports Q3 EPS of 39c, Eyes Strategic Alternatives Amid Cash Preservation Efforts

MEI Pharma reports Q3 EPS of 39 cents, a significant improvement from last year's loss of $1.37. The company is considering strategic alternatives, such as out-licensing opportunities and merger and acquisition options, to maximize its assets' value. Cash preservation efforts continue, with $20.5 million in cash and cash equivalents as of March 31, 2025.

MEI Pharma, Inc. (Nasdaq: MEIP) has reported its third-quarter fiscal year 2025 earnings per share (EPS) of -$0.39, a significant improvement from last year's loss of $1.37 [1]. The company is currently evaluating various strategic alternatives to maximize the value of its assets for shareholders. These alternatives include out-licensing opportunities for existing programs and merger and acquisition options [2].

Cash preservation efforts continue, with the company reporting $20.5 million in cash and cash equivalents as of March 31, 2025, and no outstanding debt [1, 2]. The company's operational and strategic direction is evolving, and it is implementing a reduction-in-force in stages [2].

The company's financial advisor, Oppenheimer & Co., Inc., is assisting in the evaluation process. MEI Pharma emphasizes that there is no assurance that any strategic alternatives will result in successful transactions or attractive terms [2].

MEI Pharma is a pharmaceutical company with a portfolio of drug candidates that may offer novel and differentiated cancer therapies. Its drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor [2]. The company's forward-looking statements include potential risks and uncertainties, such as the ability to identify attractive strategic alternatives and the adequacy of its capital resources [2].

References:
[1] https://seekingalpha.com/news/4447630-mei-pharma-gaap-eps-of-0_39
[2] https://www.businesswire.com/news/home/20250513634282/en/MEI-Pharma-Reports-Third-Quarter-Fiscal-Year-2025-Cash-Position